These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 29204958)

  • 21. Three-Day Field Treatment with Ingenol Disoxate (LEO 43204) for Actinic Keratosis: Cosmetic Outcomes and Patient Satisfaction from a Phase II Trial.
    Berman B; Tyring S; Nahm WK; Østerdal ML; Petersen AH; Siegel DM
    J Clin Aesthet Dermatol; 2017 Nov; 10(11):26-32. PubMed ID: 29399258
    [No Abstract]   [Full Text] [Related]  

  • 22. Evaluation of the tolerability and safety of a 0.015% ingenol mebutate gel compared to 5% 5-fluorouracil cream for the treatment of facial actinic keratosis: a prospective randomized trial.
    Samorano LP; Torezan LA; Sanches JA
    J Eur Acad Dermatol Venereol; 2015 Sep; 29(9):1822-7. PubMed ID: 25727104
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ingenol mebutate gel 0.015% and 0.05%: in actinic keratosis.
    Keating GM
    Drugs; 2012 Dec; 72(18):2397-405. PubMed ID: 23231025
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of actinic keratoses and cancerization field of the face and scalp with 0.015% ingenol mebutate gel in Brazilian individuals: safety, tolerability and patients' perspectives.
    Gameiro L; Tovo LFR; Sanches Júnior JA; Aprahamian I
    An Bras Dermatol; 2019 Jul; 94(3):313-319. PubMed ID: 31365660
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PEP005 (ingenol mebutate) gel, a novel agent for the treatment of actinic keratosis: results of a randomized, double-blind, vehicle-controlled, multicentre, phase IIa study.
    Siller G; Gebauer K; Welburn P; Katsamas J; Ogbourne SM
    Australas J Dermatol; 2009 Feb; 50(1):16-22. PubMed ID: 19178487
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Randomized, double-blind, double-dummy, vehicle-controlled study of ingenol mebutate gel 0.025% and 0.05% for actinic keratosis.
    Anderson L; Schmieder GJ; Werschler WP; Tschen EH; Ling MR; Stough DB; Katsamas J
    J Am Acad Dermatol; 2009 Jun; 60(6):934-43. PubMed ID: 19467365
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Non-invasive monitoring of subclinical and clinical actinic keratosis of face and scalp under topical treatment with ingenol mebutate gel 150 mcg/g by means of reflectance confocal microscopy and optical coherence tomography: New perspectives and comparison of diagnostic techniques.
    Ruini C; Hartmann D; Bastian M; Ruzicka T; French LE; Berking C; von Braunmühl T
    J Biophotonics; 2019 Jul; 12(7):e201800391. PubMed ID: 30653833
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and tolerability of ingenol mebutate in the treatment of actinic keratosis.
    Berman B
    Expert Opin Drug Saf; 2015; 14(12):1969-78. PubMed ID: 26524598
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ingenol mebutate gel for actinic keratosis: the link between quality of life, treatment satisfaction, and clinical outcomes.
    Augustin M; Tu JH; Knudsen KM; Erntoft S; Larsson T; Hanke CW
    J Am Acad Dermatol; 2015 May; 72(5):816-21. PubMed ID: 25770879
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reduced degree of irritation during a second cycle of ingenol mebutate gel 0.015% for the treatment of actinic keratosis.
    Jim On SC; Haddican M; Yaroshinsky A; Singer G; Lebwohl M
    Cutis; 2015 Jan; 95(1):47-51. PubMed ID: 25671445
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of facial actinic keratoses with aminolevulinic acid photodynamic therapy (ALA-PDT) or ingenol mebutate 0.015% gel with and without prior treatment with ALA-PDT.
    Berman B; Nestor MS; Newburger J; Park H; Swenson N
    J Drugs Dermatol; 2014 Nov; 13(11):1353-6. PubMed ID: 25607702
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ingenol mebutate in the treatment of actinic keratoses: clearance rate and adverse effects.
    Saraiva MIR; Portocarrero LKL; Vieira MAHB; Swiczar BCC; Westin AT
    An Bras Dermatol; 2018; 93(4):529-534. PubMed ID: 30066759
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biological Effects of Ingenol Mebutate Gel in Moderate to Severe Actinic Fields Assessed by Reflectance Confocal Microscopy: A Phase I Study.
    Ulrich M; Lange-Asschenfeldt S; Skak K; Skov T; Østerdal ML; Röwert-Huber HJ; Zibert JR; Stockfleth E
    J Drugs Dermatol; 2016 Oct; 15(10):1181-1189. PubMed ID: 27741334
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ingenol mebutate: a new option for actinic keratosis treatment.
    Gras J
    Drugs Today (Barc); 2013 Jan; 49(1):15-22. PubMed ID: 23362492
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ingenol mebutate for the treatment of actinic keratosis: effectiveness and safety in 246 patients treated in real-life clinical practice.
    Ortega Del Olmo R; Salido-Vallejo R
    J Dermatolog Treat; 2018 Jun; 29(4):393-399. PubMed ID: 28956675
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The European Medicines Agency approval of ingenol mebutate (Picato) for the cutaneous treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis in adults: summary of the scientific assessment of the Committee for Medicinal Products for Human Use (CHMP).
    Tzogani K; Nagercoil N; Hemmings RJ; Samir B; Gardette J; Demolis P; Salmonson T; Pignatti F
    Eur J Dermatol; 2014; 24(4):457-63. PubMed ID: 25115145
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ingenol mebutate as topical treatment for actinic keratosis based on a prospective, non-interventional, multicentre study of real-life clinical practice in Germany: efficacy and quality of life.
    Diepgen TL; Eicke C; Bastian M
    Eur J Dermatol; 2019 Aug; 29(4):401-408. PubMed ID: 31625920
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Real-life efficacy and safety of ingenol mebutate for the treatment of actinic keratosis of the face and scalp: A single arm retrospective study.
    Ricci F; Tambone S; Neri L; Fania L; Piccioni A; Guerriero C; Fargnoli MC; Peris K
    J Dermatolog Treat; 2016 Nov; 27(6):525-530. PubMed ID: 27043050
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Regression Analysis of Local Skin Reactions to Predict Clearance of Actinic Keratosis on the Face in Patients Treated With Ingenol Mebutate Gel: Experience from Randomized Controlled Trials.
    Jim On S; Knudsen KM; Skov T; Lebwohl M
    J Drugs Dermatol; 2017 Feb; 16(2):112-114. PubMed ID: 28300852
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tracking actinic keratosis of face and scalp treated with 0.015% ingenol mebutate to identify clinical and dermoscopic predictors of treatment response.
    Pampena R; Benati E; Borsari S; Bombonato C; Lombardi M; Raucci M; Mirra M; Lallas A; Apalla Z; Papadimitriou I; Moscarella E; Kyrgidis A; Argenziano G; Pellacani G; Longo C
    J Eur Acad Dermatol Venereol; 2018 Sep; 32(9):1461-1468. PubMed ID: 29356164
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.